STUB1 and ovarian carcinoma: HOP was implicated as a prognostic biomarker in ovarian cancer and breast cancer, and when knocked down, pancreatic, colorectal, and breast cancer cell progression decreased, highlighting how targeting HOP and likely shifting the binding occupancy of HSP70/90 to HOP and CHIP could be beneficial for cancer treatment (78, 80, 199, 200).